SkinHealth Systems (SKIN) Cash & Equivalents (2020 - 2026)

SkinHealth Systems (SKIN) has 7 years of Cash & Equivalents data on file, last reported at $204.4 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 45.22% year-over-year to $204.4 million in Q1 2026; TTM through Mar 2026 was $204.4 million, a 45.22% decrease from a year earlier, with the FY2025 full-year figure at $232.7 million, down 37.13% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $204.4 million, down from $232.7 million in the prior quarter.
• Over the last five years, Cash & Equivalents for SKIN reached as high as $859.2 million in Q1 2022 and fell as low as $204.4 million in Q1 2026.
• Historically, Cash & Equivalents has averaged $462.5 million across 5 years, with a median of $444.6 million in 2024.
• Across the five-year window, Cash & Equivalents soared 31109.19% in 2022 and slumped 45.22% in 2026, its largest moves.
• Year by year, Cash & Equivalents stood at $568.2 million in 2022, then slipped by 7.95% to $523.0 million in 2023, then fell by 29.25% to $370.1 million in 2024, then tumbled by 37.13% to $232.7 million in 2025, then dropped by 12.17% to $204.4 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $204.4 million in Q1 2026, $232.7 million in Q4 2025, and $219.4 million in Q3 2025.